In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 9, 2006, Pages 3166-3169

  Souli, Maria ^a   Kontopidou, Flora V ^a   Koratzanis, Evangelos ^a   Antoniadou, Anastasia ^a   Giannitsioti, Efthimia ^a   Evangelopoulou, Pinelopi ^a   Kannavaki, Sofia ^b   Giamarellou, Helen ^a,c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b SOTIRIA GENERAL HOSPITAL   (Greece)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; QUINUPRISTIN; SULTAMICILLIN; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; GREECE; HOSPITAL INFECTION; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; GREECE; HUMANS; MINOCYCLINE;

EID: 33748681768     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00322-06     Document Type: Article

References (18)

1. Bouchillon, S. K., D. J. Hoban, B. M. Johnson, J. L. Johnson, A. Hsiung, M. J. Dowzicky, and the Tigecycline Evaluation and Surveillance Trial (TEST) Group. 2005. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn. Microbiol. Infect. Dis. 52:173-179.
2. Bouchillon, S. K., D. J. Hoban, B. M. Johnson, T. M. Stevens, M. J. Dowzicky, D. H. Wu, and P. A. Bradford. 2005. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002. Diagn. Microbiol. Infect. Dis. 51:291-295.
3. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing, 15th informational supplement M100-S15. Clinical and Laboratory Standards Institute, Wayne, Pa.
4. Depardieu, F., P. Perichon, and P. Courvalin. 2004. Detection of the van alphabet and identification of enterococci and staphylococci at the species level by multiplex PCR. J. Clin. Microbiol. 42:5857-5860.
5. Galani, I., M. Souli, Z. Chryssouli, D. Katsala, and H. Giamarellou. 2004. First identification of an Escherichia coli clinical isolate producing both metallo-β-lactamase VIM-2 and extended-spectrum-β-lactamase IBC-1. Clin. Microbiol. Infect. 10:749-772.
6. VIM-1 and aac(6′)-11c in an Enterobacter cloacae clinical isolate from Greece. J. Antimicrob. Chemother. 55:634-638.
7. Gales, A. C., A. O. Reis, and R. N. Jones. 2001. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J. Clin. Microbiol. 39:183-190.
8. Giakkoupi, P., A. Xanthaki, M. Kanelopoulou, A. Vlahaki, V. Miriagou, S. Kontou, E. Papafraggas, H. Malamou-Lada, L. S. Tzouvelekis, N. J. Legakis, and A. C. Vatopoulos. 2003. VIM-1 metallo-β-lactamase-producing Klebsiella pneumoniae strains in Greek hospitals. J. Clin. Microbiol. 41:3893-3896.
9. Giamarellou, H. 2005. Multidrug resistance in Gram-negative bacteria that produce extended-spectrum-beta-lactamases (ESBLs). Clin. Microbiol. Infect. 11(Suppl. 4):S1-S16.
10. Herrero, I. A., N. C. Issa, and R. Patel. 2002. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N. Engl. J. Med. 346:867-869.
11. VIM-1 metallo-β-lactamase gene. J. Clin. Microbiol. 43:5344-5347.
12. Lee, K., Y. Chong, H. B. Shin, Y. A. Kim, D. Yong, and J. H. Yum. 2001. Modified Hodge and EDTA-disk synergy tests to screen metallo-beta-lactamase- producing strains of Pseudomonas and Acinetobacter species. Clin. Microbiol. Infect. 7:88-91.
13. Livermore, D. L. 2005. Tigecycline: what is it, and where should it be used? J. Antimicrob. Chemother. 56:611-614.
14. Miriagou, V., E. Tzelepi, G. L. Daikos, P. T. Tassios, and L. S. Tzouvelekis. 2005. Panresistance in VIM-1-producing Klebsiella pneumoniae. J. Antimicrob. Chemother. 55:810-811.
15. Reis, A. O., D. A. M. Luz, M. C. B. Tognim, H. S. Sader, and A. C. Gales. 2003. Polymyxin-resistant Acinetobacter spp. isolates: what is next? Emerg. Infect. Dis. 9:1025-1027.
16. Sturenburg, E., and D. Mack. 2003. Extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control. J. Infect, 47:273-295.
17. Tuckman, M., P. J. Petersen, and S. J. Projan. 2000. Mutations in the interdomain loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines. Microb. Drug Resist. 6:277-282.
18. Walsh, T. R. 2005. The emergence and implications of metallo-beta- lactamases in Gram-negative bacteria. Clin. Microbiol. Infect. 11(Suppl. 6):S2-S9.